A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Agitation; Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 13 Oct 2017 Status changed from recruiting to discontinued.
    • 25 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top